+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Ocular Drug Delivery: Market Overview, Delivery Technologies and Partnering Opportunities, 2nd edition

  • ID: 5221335
  • Report
  • November 2020
  • Region: Global
  • 199 Pages
  • MCD Group LLC

FEATURED COMPANIES

  • 20/20 OptimEyes
  • CIS Pharma
  • EyePoint Pharmaceuticals
  • Kala Pharmaceuticals
  • Nemera
  • Re-Vana Therapeutics

Millions of people worldwide are affected by various eye diseases, and given the anatomic and physiologic barriers of the eye, effective delivery of ocular therapeutics can be challenging. The majority of ocular pharmaceutical treatments are delivered as topical formulations which tend to be highly inefficient and difficult to administer properly. Injectable formulations are available to a lesser extent and can be associated with serious side effects and require administration by a medical professional.

Fortunately there are more than 50 companies developing improved ocular delivery systems which provide benefits such as sustained release, enhanced penetration into ocular tissue, accurate dosing, and ease of administration. These companies range from emerging start-ups with preclinical projects to established specialty and multinational companies with late-stage pipeline products. There are also numerous University research groups innovating in the ocular space.  Collectively, they have more than 80 novel ocular formulations and products in various stages of development for indications such as glaucoma, uveitis, macular degeneration, and dry eye disease.

This report provides an overview of the ocular drug delivery market and in-depth profiles of innovative formulation and device technologies currently in development. Additionally, the report highlights the various company and University technologies which are available for partnering. Examples of novel technologies presented: “smart” eye drop devices, punctal plugs, drug-eluting lenses, mucoadhesive nanoparticles and micelles, episcleral implants, micro-injectors, antibody biopolymer conjugates, and sustained release implants and depots.

Report Contents:

Eye Diseases

  • Overview and prevalence data
  • Age-related macular degeneration
  • Macular edema and diabetic retinopathy
  • Glaucoma
  • Inflammatory conditions

Market Overview

  • US Ophthalmic Market by Product Type
  • Top-selling prescription ophthalmic products, 2019
  • Key players
  • Ophthalmic revenues and drug delivery products

Ophthalmic Drug Delivery Landscape

  • Non-invasive delivery technologies
  • Eye drops/solutions, ocular inserts, punctal plugs, drug-loaded lenses
  • Invasive delivery technologies
  • Intravitreal injections, implants, suprachoroidal injectors
  • Approved ocular drug delivery products (US)
  • Ocular drug delivery pipeline
  • Glaucoma
  • Uveitis and macular edema
  • Ocular inflammation
  • Age-related macular degeneration
  • Dry eye disease
  • Novel therapeutics and indications
  • Development opportunities
  • Future perspectives

Technology Profiles – 50+ Companies

  • Examples of companies included:
  • Aerie Pharmaceuticals
  • AesculaTech
  • Amorphex Therapeutics
  • Clearside Biomedical
  • Congruence Medical
  • Eximore Ltd.
  • EyeGate Pharma
  • Eyenovia
  • EyePoint Pharmaceuticals
  • Glaukos
  • Graybug Vision
  • iVeena Delivery Systems
  • iView Therapeutics
  • Kala Pharmaceuticals
  • Kedalion Therapeutics
  • Kodiak Biosciences
  • Leo Lens Pharma
  • Mati Therapeutics
  • MuPharma
  • Nemera
  • Novaliq
  • Ocular Therapeutix
  • Oculis
  • PolyActiva
  • Re-Vana Therapeutics
  • Santen Pharmaceuticals
  • Sun Ophthalmics
  • TALLC
  • TearClear
  • VisusNano

For each company profiled, the following information is provided:

  • Technology description
  • Development stage
  • Competitive advantage
  • Patents
  • Company description
  • Partnerships
  • Contact information for partnering

Reasons to buy:

  • Identify enabling delivery systems or devices for pipeline drugs
  • Scout enhancing technologies for LCM of marketed ophthalmic drugs
  • Understand the key players and therapeutic segments
  • Obtain product and technology information for launched ophthalmics
  • View pipeline details for novel ocular formulations in development
  • Discover product and technology licensing opportunities
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • 20/20 OptimEyes
  • CIS Pharma
  • EyePoint Pharmaceuticals
  • Kala Pharmaceuticals
  • Nemera
  • Re-Vana Therapeutics

Introduction  

Chapter I: Eye Diseases

  • Age-Related Macular Degeneration (AMD)
  • Macular Edema and Diabetic Retinopathy
  • Glaucoma
  • Inflammatory Conditions
  • Dry Eye Disease

Chapter II:  Market Overview

  • Key Players

Chapter III:  Ophthalmic Drug Delivery Landscape

  • Non-Invasive Delivery Technologies
  • Invasive Delivery Technologies
  • Approved Ocular DDS Products
  • Ocular DDS Pipeline
  • Glaucoma
  • Uveitis and Macular Edema
  • Ocular Inflammation
  • Age-Related Macular Degeneration
  • Dry Eye Disease
  • Novel Therapies & Indications
  • Development Opportunities
  • Future Perspectives

Chapter IV: Technology Profiles

  • Novel Aerosol & Eye Drop Devices
  • Aero Pump
  • CIS Pharma
  • Eyenovia
  • Kedalion Therapeutics
  • Nemera
  • Zeteo Biomedical
  • Punctal Plugs & Ocular Inserts
  • AesculaTech
  • Amorphex Therapeutics
  • BioLight Life Sciences
  • Eximore
  • Mati Therapeutics
  • Ocular Therapeutix
  • Topical Delivery Systems
  • 20/20 OptimEyes
  • Aciont
  • EyeCRO
  • EyeGate Pharma
  • Integral Ophthalmics
  • iView Therapeutics
  • Kala Pharmaceuticals
  • Nanomerics
  • Novaliq
  • Oculis
  • MC2 Therapeutics
  • MuPharma
  • Santen Pharmaceuticals
  • Sun Ophthalmics
  • Surface Pharmaceuticals
  • TALLC
  • TearClear
  • Injectables & Implants
  • 3T Ophthalmics
  • Abbvie
  • Aerie Pharmaceuticals
  • Clearside Biomedical
  • Congruence Medical
  • DelSiTech
  • EyePoint Pharmaceuticals
  • Eyevensys
  • Glaukos
  • Graybug Vision
  • iVeena Delivery Systems
  • Kodiak Biosciences
  • LayerBio
  • Nanogenics
  • Neurotech Pharmaceuticals
  • OcuJect
  • PolyActiva
  • Re-Vana Therapeutics
  • Roche
  • TLC Bio
  • VisusNano
  • Drug Eluting Lenses
  • Glint Pharmaceuticals
  • Leo Lens Pharma
  • OcuMedic

Chapter V: University Technologies

  • Johns Hopkins University: Retinal Implantation Device
  • Johns Hopkins University: Canalicular Delivery System
  • Ohio State University: Bi-layered Capsule
  • Stanford University: Injectable Deformable Hydrogels
  • University of Colorado: Nanogel Ophthalmic Delivery Devices
  • University of Florida: Oleogel Technology
  • University of Michigan: PLGA-Coated Ocular Implants
  • University of North Carolina: Ceria Nanoparticles
  • University of Pittsburgh: CyteSolutions Lens
  • University of Pittsburgh: Reverse Thermal Gels

Table & Figures
Figure 1:  Eye Disease Prevalence, US
Table 1:  Wet AMD Therapeutics
Table 2:  Injectable Steroids for Macular Edema
Table 3:  Topical Glaucoma Products
Table 4:  Ocular Anti-inflammatory Products
Table 5: Prescription Dry Eye Treatments
Figure 2:  US Ophthalmic Market by Product Type, 2019
Table 6:  Top-Selling Prescription Ophthalmic Products, 2019
Figure 3:  Ophthalmic Revenues of Key Players, 2019
Figure 4:  Key Players with Ocular DDS Products
Table 7:  Comparison of Non-Invasive Ocular DDS
Figure 5: Durysta® Injector and Implant
Table 8:  Comparison of Invasive Ocular DDS
Table 9: Approved Ophthalmic DDS Products, US
Figure 6:  Timeline for Approved SR Ocular Implants in the US
Table 10:  Topical Glaucoma DDS Pipeline
Table 11: Sustained Release Glaucoma Pipeline
Figure 7: Clearside Bio SCS Microinjector
Table 12: Uveitis and Macular Edema DDS Pipeline
Table 13:  Ocular Pain and Inflammation DDS Pipeline
Table 14: Macular Degeneration DDS Pipeline
Table 15: Dry Eye DDS Pipeline
Table 16: Novel Therapies Pipeline
Table 17:  Examples of Ophthalmic Candidates for Long-Acting Delivery
Figure 8: Medspray Spray Nozzle Unit
Figure 9: CIS Pharma Connected Dispenser
Figure 10: Eyenovia Microdose Dispenser
Table 18:  Eyenovia Pipeline
Table 19: Optejet vs Standard Eye Dropper
Figure 11: Depiction of AcuStream Patient Administration
Table 20: Kedalion Pipeline
Figure 12: e-Novelia Smart Add-On
Figure 13: AquilaMD Ophthalmic Device
Figure 14: AesculaGel and Applicator
Figure 15: TODDD matrix
Figure 16: TODDD drug depots
Table 21: Amorphex Pipeline
Table 22: TODDD Competitive Comparison
Figure 17: Eximore punctal plug
Table 23: Eximore Pipeline
Figure 18: Inserting the Evolute plug
Table 24: Mati Therapeutics Pipeline
Figure 19: Punctum Plug Depot
Table 25: Ocular Therapeutix Pipeline
Figure 20: Visulex-P Applicator
Figure 21: Visulex-I Platform and General Visulex Process
Figure 22: Aciont MRI study
Table 26:  Aciont Pipeline
Figure 23: MiDROPS illustration
Figure 24: CMHA-S composition
Table 27: EyeGate Pipeline
Table 28: iView Pipeline
Figure 25: Proprietary Attributes of AMMPLIFY Technology
Table 29:  Kala Pipeline
Figure 26: MET Design and Process
Table 30: Novaliq Pipeline
Table 31: Santen Ophthalmic DDS Pipeline
Table 32: Sun Ophthalmic DDS Products
Table 33:  Surface Pharmaceuticals Pipeline
Figure 27: SmartCelle Delivery Schematic
Table 34:  TALLC Pipeline
Figure 28: Diagram of Common Ocular Drug Delivery Systems
Figure 29: Visual of the Episcleral System
Table 35: 3T Product Pipeline
Figure 30: Photographs of the Sustained Release Bimatoprost SR Implant
Figure 31: PRINT technology
Table 36:  Aerie Pipeline
Figure 32: SCS Microinjector
Table 37: Clearside Biomedical Pipeline
Figure 33: MDS Shown with Various 1 mL Long Prefillable Syringes
Figure 34: Durasert Implant
Table 38: EyePoint Pipeline
Table 39: Eyevensys Pipeline
Figure 35: Two Generations of iDose Implants
Table 40: Glaukos Pipeline
Figure 36: Graybug Microparticle Depot
Table 41:  Graybug Pipeline
Figure 37: iVeena Bioerodible Implant
Figure 38: Kodiak ABC Platform
Figure 39: Molecular Properties of KSI-301
Table 42: Kodiak ABC Pipeline
Figure 40: LayerForm Assembly
Figure 41: PolyNet Illustration
Table 43: LayerBio Pipeline
Figure 42: ECT Platform Schematic
Table 44:  Neurotech Pipeline
Figure 43: Classes of Therapeutics Supported by ECT Technology
Figure 44: SteriCap Mini Needle
Table 45:  PolyActiva Ophthalmic Pipeline
Figure 45: EyeLief Mechanism of Drug Release
Table 46: Benefits of Re-Vana Delivery Systems
Figure 46: The PDS Implant in Position
Figure 47: Injection Demonstration for TLC399
Figure 48: Schematic of Leo Lens MediPrint Process
Table 47:  Leo Lens Pipeline
Table 48:  Leo Lens Technology Advantages
Figure 49: OcuMedic Novel Lens Technology
Table 49:  OcuMedic Pipeline

Note: Product cover images may vary from those shown
  • 20/20 OptimEyes
  • 3T Ophthalmics
  • Abbvie
  • Aciont
  • Aerie Pharmaceuticals
  • AesculaTech
  • Amorphex Therapeutics
  • BioLight Life Sciences
  • CIS Pharma
  • Clearside Biomedical
  • Congruence Medical
  • DelSiTech
  • Eximore
  • EyeCRO
  • EyeGate Pharma
  • EyePoint Pharmaceuticals
  • Eyenovia
  • Eyevensys
  • Glaukos
  • Glint Pharmaceuticals
  • Graybug Vision
  • Integral Ophthalmics
  • Kala Pharmaceuticals
  • Kedalion Therapeutics
  • Kodiak Biosciences
  • LayerBio
  • Leo Lens Pharma
  • MC2 Therapeutics
  • Mati Therapeutics
  • MuPharma
  • Nemera
  • Neurotech Pharmaceuticals
  • Novaliq
  • Novel Aerosol & Eye Drop Devices
  • OcuJect
  • OcuMedic
  • Ocular Therapeutix
  • Oculis
  • PolyActiva
  • Re-Vana Therapeutics
  • Roche
  • Santen Pharmaceuticals
  • Sun Ophthalmics
  • TALLC
  • TLC Bio
  • TearClear
  • VisusNano
  • Zeteo Biomedical
  • iVeena Delivery Systems
  • iView Therapeutics
Note: Product cover images may vary from those shown
Adroll
adroll